Effects of CYP2C19*2 polymorphisms on the efficacy and safety of phenazepam in patients with anxiety disorder and comorbid alcohol use disorder

Michael S. Zastrozhin, Valentin Y. Skryabin, Marco Torrado, Anastasiya Petrovna, Alexander S. Sorokin, Elena A. Grishina, Kristina A. Ryzhikova, Inessa A. Bedina, Oleg Z. Buzik, Egor M. Chumakov, Ludmila M. Savchenko, Evgeny A. Brun, Dmitry A. Sychev

Research output

Abstract

Introduction: Phenazepam therapy can often be ineffective and some patients develop dose-related adverse drug reactions. Aim. The purpose of this research was to study the effect of the CYP2C19*2 (681G>A, rs4244285) in patients with anxiety disorders and alcohol dependence taking phenazepam therapy. Materials & methods: Patients (175 males, average age: 37.16 ± 7.84 years) received phenazepam in tablet form for 5 days. Genotyping was performed by real-Time polymerase chain reaction. Results: The statistically significant differences in the UKU Side-Effect Rating Scale scores on the fifth day of therapy: (CYP2C19*1/*1) 2.00 [1.00; 2.00), (CYP2C19*1/*2) 7.00 (7.00; 7.00), (CYP2C19*2/*2) 9.00 (8.00; 9.00), p < 0.001. Conclusion: This study demonstrated the different efficacy and safety of phenazepam in patients with different genotypes of CYP2C19*2.

Original languageEnglish
Pages (from-to)111-123
Number of pages13
JournalPharmacogenomics
Volume21
Issue number2
Early online date20 Jan 2020
DOIs
Publication statusPublished - 2020

Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Pharmacology

Fingerprint Dive into the research topics of 'Effects of CYP2C19*2 polymorphisms on the efficacy and safety of phenazepam in patients with anxiety disorder and comorbid alcohol use disorder'. Together they form a unique fingerprint.

  • Cite this

    Zastrozhin, M. S., Skryabin, V. Y., Torrado, M., Petrovna, A., Sorokin, A. S., Grishina, E. A., Ryzhikova, K. A., Bedina, I. A., Buzik, O. Z., Chumakov, E. M., Savchenko, L. M., Brun, E. A., & Sychev, D. A. (2020). Effects of CYP2C19*2 polymorphisms on the efficacy and safety of phenazepam in patients with anxiety disorder and comorbid alcohol use disorder. Pharmacogenomics, 21(2), 111-123. https://doi.org/10.2217/pgs-2019-0019, https://doi.org/10.2217/pgs-2019-0019